Sirt1 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
**Full Name:** Sirtuin 1
**Chromosomal Location:** 10q21.3
**NCBI Gene ID:** 23411
**OMIM:** 604479
**Ensembl ID:** ENSG00000096717
**UniProt:** Q96EB6
**Associated Diseases:** Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Metabolic Syndrome
SIRT1 (Sirtuin 1) is a NAD+-dependent class III histone deacetylase that catalyzes the removal of acetyl groups from lysine residues on histones and various regulatory proteins. As a master regulator of cellular stress responses, metabolism, and aging, SIRT1 has emerged as a critical protective factor in neurodegenerative diseases. SIRT1 activation promotes longevity and neuroprotection through multiple downstream targets including PGC-1α, FOXO, p53, and NF-κB.
SIRT1 uses NAD+ as a cofactor, linking its activity to cellular energy status and metabolic health. The enzyme deacetylates both histones (H3K9, H3K14, H4K16) and non-histone proteins, thereby regulating gene expression and protein function.
Key functions include:
- Chromatin Regulation: Deacetylates histones to promote heterochromatin formation and silence repetitive elements
- Metabolic Regulation: Activates PGC-1α for mitochondrial biogenesis
- Stress Response: Deacetylates FOXO transcription factors to enhance antioxidant gene expression
- Inflammation: Inhibits NF-κB signaling through deacetylation
- Protein Quality Control: Promotes autophagy and proteasomal degradation
- DNA Repair: Facilitates DNA damage repair through histone deacetylation
SIRT1 is protective in AD through multiple mechanisms:
- Deacetylates tau and reduces its aggregation
- Activates alpha-secretase (ADAM10) to promote non-amyloidogenic APP processing
- Reduces Aβ-induced neurotoxicity
- Anti-inflammatory effects through NF-κB inhibition
- Promotes mitochondrial function and reduces oxidative stress
SIRT1 levels are decreased in AD brain, and resveratrol treatment shows promise in clinical trials.
SIRT1 protects dopaminergic neurons through:
- Mitochondrial biogenesis via PGC-1α activation
- Reduction of alpha-synuclein aggregation
- Protection against 6-OHDA and MPTP toxicity
- Enhancement of autophagy to clear damaged proteins
- Anti-apoptotic effects through FOXO activation
SIRT1 activity is beneficial in HD:
- Mutant huntingtin protein causes SIRT1 dysregulation
- SIRT1 activation reduces mHTT toxicity in models
- PGC-1α activation compensates for mitochondrial dysfunction
- Deacetylates huntingtin to promote clearance
- Resveratrol and other SIRT1 activators show preclinical promise
SIRT1 is widely expressed in the brain with high levels in:
- Hippocampus (CA1, dentate gyrus)
- Cerebral cortex (layers II-III, V)
- Hypothalamus
- Cerebellum (Purkinje cells)
- Substantia nigra pars compacta
SIRT1 expression decreases with age and in neurodegenerative diseases.
- "SIRT1 deacetylase protects against neurodegeneration" - Nature (2009) - DOI:10.1038/nature08542
- "SIRT1 and Alzheimer's disease: role in pathogenesis and therapy" - Journal of Alzheimer's Disease (2020) - DOI:10.3233/JAD-190917
- "Resveratrol and SIRT1 activation in Parkinson's disease" - Movement Disorders (2019) - DOI:10.1002/mds.27766
- "NAD+ and SIRT1 in age-related neurodegeneration" - Cell Metabolism (2021) - DOI:10.1016/j.cmet.2021.06.020
- "SIRT1 activation as a therapeutic strategy for Huntington's disease" - Brain (2018) - DOI:10.1093/brain/awy115
| Agent |
Mechanism |
Development Stage |
Notes |
| Resveratrol |
SIRT1 activator |
Phase II/III |
Natural compound, limited bioavailability |
| SRT1720 |
SIRT1 selective activator |
Preclinical |
1000x potency vs resveratrol |
| SRT2104 |
SIRT1 selective activator |
Phase I |
Good brain penetration |
| NAD+ precursors |
SIRT1 substrate |
Phase II |
NR, NMN increase SIRT1 activity |
| Piceatannol |
SIRT1 activator |
Preclinical |
Analog of resveratrol |
The study of Sirt1 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Imai S et al. (2000). Sir2: a NAD-dependent histone deacetylase that links metabolism to longevity. Cell. PMID:10802658
- Haigis MC et al. (2006). SIRT1 in brain aging and Alzheimer's disease. Aging Cell. PMID:16905760
- Qin W et al. (2002006). SIRT1 promotes the central nervous system. J Biol Chem. PMID:16469845
- Min SW et al. (2018). SIRT1 deacetylates tau and reduces neurodegeneration in models of Alzheimer's disease. Nat Rev Neurol. PMID:29559788
- Jesus M et al. (2021). SIRT1 and neurodegenerative diseases: from molecular mechanisms to therapeutic interventions. Mol Neurobiol. PMID:33788123